|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 29142 |
FusionGeneSummary for PSMB7_ZFP36 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: PSMB7_ZFP36 | Fusion gene ID: 29142 | Hgene | Tgene | Gene symbol | PSMB7 | ZFP36 | Gene ID | 5695 | 7538 |
| Gene name | proteasome subunit beta 7 | ZFP36 ring finger protein | |
| Synonyms | Z | G0S24|GOS24|NUP475|RNF162A|TIS11|TTP|zfp-36 | |
| Cytomap | 9q33.3 | 19q13.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | proteasome subunit beta type-7macropain chain Zmulticatalytic endopeptidase complex chain Zproteasome (prosome, macropain) subunit, beta type, 7proteasome catalytic subunit 2proteasome subunit Zproteasome subunit alphaprotein serine kinase c17 | mRNA decay activator protein ZFP36G0/G1 switch regulatory protein 24growth factor-inducible nuclear protein NUP475tristetraprolintristetraprolinezinc finger protein 36 homologzinc finger protein 36, C3H type, homologzinc finger protein, C3H type, 3 | |
| Modification date | 20180523 | 20180523 | |
| UniProtAcc | Q99436 | P26651 | |
| Ensembl transtripts involved in fusion gene | ENST00000498485, ENST00000259457, ENST00000536392, | ENST00000597629, ENST00000248673, ENST00000594045, | |
| Fusion gene scores | * DoF score | 7 X 7 X 4=196 | 6 X 6 X 1=36 |
| # samples | 8 | 6 | |
| ** MAII score | log2(8/196*10)=-1.29278174922785 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(6/36*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: PSMB7 [Title/Abstract] AND ZFP36 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | ZFP36 | GO:0000288 | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 23644599 |
| Tgene | ZFP36 | GO:0006402 | mRNA catabolic process | 10330172|10751406|11782475|20221403 |
| Tgene | ZFP36 | GO:0009611 | response to wounding | 27182009 |
| Tgene | ZFP36 | GO:0031086 | nuclear-transcribed mRNA catabolic process, deadenylation-independent decay | 11279239 |
| Tgene | ZFP36 | GO:0032680 | regulation of tumor necrosis factor production | 15014438 |
| Tgene | ZFP36 | GO:0042594 | response to starvation | 15014438 |
| Tgene | ZFP36 | GO:0043488 | regulation of mRNA stability | 9703499|11719186|15687258|20702587 |
| Tgene | ZFP36 | GO:0044344 | cellular response to fibroblast growth factor stimulus | 20166898 |
| Tgene | ZFP36 | GO:0045647 | negative regulation of erythrocyte differentiation | 20702587 |
| Tgene | ZFP36 | GO:0060213 | positive regulation of nuclear-transcribed mRNA poly(A) tail shortening | 10330172 |
| Tgene | ZFP36 | GO:0061158 | 3'-UTR-mediated mRNA destabilization | 9703499|11719186|15687258|20221403|27193233 |
| Tgene | ZFP36 | GO:0070935 | 3'-UTR-mediated mRNA stabilization | 15014438 |
| Tgene | ZFP36 | GO:0071222 | cellular response to lipopolysaccharide | 14766228 |
| Tgene | ZFP36 | GO:0071356 | cellular response to tumor necrosis factor | 20166898 |
| Tgene | ZFP36 | GO:0071364 | cellular response to epidermal growth factor stimulus | 20166898 |
| Tgene | ZFP36 | GO:0071385 | cellular response to glucocorticoid stimulus | 20166898 |
| Tgene | ZFP36 | GO:0097011 | cellular response to granulocyte macrophage colony-stimulating factor stimulus | 20166898 |
| Tgene | ZFP36 | GO:1900153 | positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 12748283 |
| Tgene | ZFP36 | GO:1901835 | positive regulation of deadenylation-independent decapping of nuclear-transcribed mRNA | 16364915 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | BM990034 | PSMB7 | chr9 | 127115955 | + | ZFP36 | chr19 | 39899603 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3UTR | ENST00000498485 | ENST00000597629 | PSMB7 | chr9 | 127115955 | + | ZFP36 | chr19 | 39899603 | + |
| intron-3UTR | ENST00000498485 | ENST00000248673 | PSMB7 | chr9 | 127115955 | + | ZFP36 | chr19 | 39899603 | + |
| intron-intron | ENST00000498485 | ENST00000594045 | PSMB7 | chr9 | 127115955 | + | ZFP36 | chr19 | 39899603 | + |
| intron-3UTR | ENST00000259457 | ENST00000597629 | PSMB7 | chr9 | 127115955 | + | ZFP36 | chr19 | 39899603 | + |
| intron-3UTR | ENST00000259457 | ENST00000248673 | PSMB7 | chr9 | 127115955 | + | ZFP36 | chr19 | 39899603 | + |
| intron-intron | ENST00000259457 | ENST00000594045 | PSMB7 | chr9 | 127115955 | + | ZFP36 | chr19 | 39899603 | + |
| intron-3UTR | ENST00000536392 | ENST00000597629 | PSMB7 | chr9 | 127115955 | + | ZFP36 | chr19 | 39899603 | + |
| intron-3UTR | ENST00000536392 | ENST00000248673 | PSMB7 | chr9 | 127115955 | + | ZFP36 | chr19 | 39899603 | + |
| intron-intron | ENST00000536392 | ENST00000594045 | PSMB7 | chr9 | 127115955 | + | ZFP36 | chr19 | 39899603 | + |
Top |
FusionProtFeatures for PSMB7_ZFP36 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| PSMB7 | ZFP36 |
| Component of the 20S core proteasome complex involved inthe proteolytic degradation of most intracellular proteins. Thiscomplex plays numerous essential roles within the cell byassociating with different regulatory particles. Associated withtwo 19S regulatory particles, forms the 26S proteasome and thusparticipates in the ATP-dependent degradation of ubiquitinatedproteins. The 26S proteasome plays a key role in the maintenanceof protein homeostasis by removing misfolded or damaged proteinsthat could impair cellular functions, and by removing proteinswhose functions are no longer required. Associated with the PA200or PA28, the 20S proteasome mediates ubiquitin-independent proteindegradation. This type of proteolysis is required in severalpathways including spermatogenesis (20S-PA200 complex) orgeneration of a subset of MHC class I-presented antigenic peptides(20S-PA28 complex). Within the 20S core complex, PSMB7 displays atrypsin-like activity. {ECO:0000269|PubMed:15244466,ECO:0000269|PubMed:27176742, ECO:0000269|PubMed:8610016}. | Zinc-finger RNA-binding protein that destabilizesseveral cytoplasmic AU-rich element (ARE)-containing mRNAtranscripts by promoting their poly(A) tail removal ordeadenylation, and hence provide a mechanism for attenuatingprotein synthesis (PubMed:9703499, PubMed:10330172,PubMed:10751406, PubMed:11279239, PubMed:12115244,PubMed:12748283, PubMed:15187101, PubMed:15634918,PubMed:17030620, PubMed:16702957, PubMed:20702587,PubMed:20221403, PubMed:21775632, PubMed:27193233,PubMed:23644599, PubMed:25815583). Acts as an 3'-untranslatedregion (UTR) ARE mRNA-binding adapter protein to communicatesignaling events to the mRNA decay machinery (PubMed:15687258,PubMed:23644599). Recruits deadenylase CNOT7 (and probably theCCR4-NOT complex) via association with CNOT1, and hence promotesARE-mediated mRNA deadenylation (PubMed:23644599). Functions alsoby recruiting components of the cytoplasmic RNA decay machinery tothe bound ARE-containing mRNAs (PubMed:11719186, PubMed:12748283,PubMed:15687258, PubMed:16364915). Self regulates by destabilizingits own mRNA (PubMed:15187101). Binds to 3'-UTR ARE of numerousmRNAs and of its own mRNA (PubMed:10330172, PubMed:10751406,PubMed:12115244, PubMed:15187101, PubMed:15634918,PubMed:17030620, PubMed:16702957, PubMed:19188452,PubMed:20702587, PubMed:20221403, PubMed:21775632,PubMed:25815583). Plays a role in anti-inflammatory responses;suppresses tumor necrosis factor (TNF)-alpha production bystimulating ARE-mediated TNF-alpha mRNA decay and several otherinflammatory ARE-containing mRNAs in interferon (IFN)- and/orlipopolysaccharide (LPS)-induced macrophages (By similarity).Plays also a role in the regulation of dendritic cell maturationat the post-transcriptional level, and hence operates as part of anegative feedback loop to limit the inflammatory response(PubMed:18367721). Promotes ARE-mediated mRNA decay of hypoxia-inducible factor HIF1A mRNA during the response of endothelialcells to hypoxia (PubMed:21775632). Positively regulates earlyadipogenesis of preadipocytes by promoting ARE-mediated mRNA decayof immediate early genes (IEGs) (By similarity). Negativelyregulates hematopoietic/erythroid cell differentiation bypromoting ARE-mediated mRNA decay of the transcription factorSTAT5B mRNA (PubMed:20702587). Plays a role in maintainingskeletal muscle satellite cell quiescence by promoting ARE-mediated mRNA decay of the myogenic determination factor MYOD1mRNA (By similarity). Associates also with and regulates theexpression of non-ARE-containing target mRNAs at the post-transcriptional level, such as MHC class I mRNAs(PubMed:18367721). Participates in association with argonaute RISCcatalytic components in the ARE-mediated mRNA decay mechanism;assists microRNA (miRNA) targeting ARE-containing mRNAs(PubMed:15766526). May also play a role in the regulation ofcytoplasmic mRNA decapping; enhances decapping of ARE-containingRNAs, in vitro (PubMed:16364915). Involved in the delivery oftarget ARE-mRNAs to processing bodies (PBs) (PubMed:17369404). Inaddition to its cytosolic mRNA-decay function, affects nuclearpre-mRNA processing (By similarity). Negatively regulates nuclearpoly(A)-binding protein PABPN1-stimulated polyadenylation activityon ARE-containing pre-mRNA during LPS-stimulated macrophages (Bysimilarity). Also involved in the regulation of stress granule(SG) and P-body (PB) formation and fusion (By similarity). Plays arole in the regulation of keratinocyte proliferation,differentiation and apoptosis (PubMed:27182009). Plays a role as atumor suppressor by inhibiting cell proliferation in breast cancercells (PubMed:26926077). {ECO:0000250|UniProtKB:P22893,ECO:0000269|PubMed:10330172, ECO:0000269|PubMed:10751406,ECO:0000269|PubMed:11279239, ECO:0000269|PubMed:11719186,ECO:0000269|PubMed:12115244, ECO:0000269|PubMed:12748283,ECO:0000269|PubMed:15187101, ECO:0000269|PubMed:15634918,ECO:0000269|PubMed:15687258, ECO:0000269|PubMed:15766526,ECO:0000269|PubMed:16364915, ECO:0000269|PubMed:16702957,ECO:0000269|PubMed:17030620, ECO:0000269|PubMed:17369404,ECO:0000269|PubMed:18367721, ECO:0000269|PubMed:19188452,ECO:0000269|PubMed:20221403, ECO:0000269|PubMed:20702587,ECO:0000269|PubMed:21775632, ECO:0000269|PubMed:23644599,ECO:0000269|PubMed:25815583, ECO:0000269|PubMed:26926077,ECO:0000269|PubMed:27182009, ECO:0000269|PubMed:27193233,ECO:0000269|PubMed:9703499}. (Microbial infection) Negatively regulates HTLV-1 TAX-dependent transactivation of viral long terminal repeat (LTR)promoter. {ECO:0000269|PubMed:14679154}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for PSMB7_ZFP36 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for PSMB7_ZFP36 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for PSMB7_ZFP36 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for PSMB7_ZFP36 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | ZFP36 | C0006625 | Cachexia | 2 | CTD_human |
| Tgene | ZFP36 | C0002170 | Alopecia | 1 | CTD_human |
| Tgene | ZFP36 | C0003864 | Arthritis | 1 | CTD_human |
| Tgene | ZFP36 | C0011603 | Dermatitis | 1 | CTD_human |
| Tgene | ZFP36 | C0020507 | Hyperplasia | 1 | CTD_human |
| Tgene | ZFP36 | C0021368 | Inflammation | 1 | CTD_human |
| Tgene | ZFP36 | C0027626 | Neoplasm Invasiveness | 1 | CTD_human |
| Tgene | ZFP36 | C0151744 | Myocardial Ischemia | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|